Valuation: AbbVie Inc.

Market Cap 462B 411B 384B 350B 659B 44,507B 668B 4,645B 1,798B 22,667B 1,736B 1,698B 72,803B P/E 2026 *
33.1x
P/E 2027 * 24.7x
Enterprise Value 524B 465B 435B 397B 746B 50,437B 757B 5,264B 2,038B 25,687B 1,967B 1,924B 82,504B EV / Sales 2026 *
7.75x
EV / Sales 2027 * 7.01x
Free-Float
95.71%
Yield 2026 *
2.65%
Yield 2027 * 2.76%
1 week-0.66%
Current month+4.89%
1 month+4.94%
3 months+5.70%
6 months+24.44%
Current year+18.00%
1 week 229.35
Extreme 229.35
235.5
1 month 211.7
Extreme 211.7
235.5
3 years 125.3
Extreme 125.3
235.5
5 years 91.94
Extreme 91.94
235.5
10 years 0
Extreme 0
235.5
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%-0.66%+17.05%+64.01% 462B
-0.62%-2.71%+39.30%+113.61% 1,031B
-2.30%-4.44%+39.03%+66.72% 638B
-0.63%-1.96%+6.36%+75.33% 462B
-1.03%-2.82%+59.56%+40.23% 359B
-0.03%-3.91%+34.28%+39.35% 335B
-1.58%+0.39%+17.92%+25.77% 273B
-2.02%-3.20%+7.60%+8.38% 253B
-3.38%+0.30%+36.44%+52.93% 228B
-1.04%-1.46%+32.70%+99.06% 185B
Average -1.20%-0.36%+29.02%+58.54% 418.21B
Weighted average by Cap. -0.99%-0.35%+30.82%+68.92%

Financials

2026 *2027 *
Net sales 67.6B 60.04B 56.15B 51.17B 96.33B 6,509B 97.65B 679B 263B 3,315B 254B 248B 10,647B 73.5B 65.28B 61.05B 55.63B 105B 7,076B 106B 739B 286B 3,604B 276B 270B 11,575B
Net income 14.07B 12.49B 11.68B 10.65B 20.05B 1,354B 20.32B 141B 54.72B 690B 52.81B 51.67B 2,215B 19.05B 16.92B 15.82B 14.42B 27.14B 1,834B 27.51B 191B 74.09B 934B 71.51B 69.96B 3,000B
Net Debt 61.59B 54.71B 51.16B 46.62B 87.77B 5,930B 88.98B 619B 240B 3,020B 231B 226B 9,701B 53.09B 47.16B 44.1B 40.19B 75.66B 5,112B 76.7B 533B 207B 2,603B 199B 195B 8,362B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
-
Date Price Change
26-10-01 €231.55 -0.09%
26-09-30 €231.75 +0.04%
26-09-29 €231.65 -1.47%
26-09-28 €235.10 +1.60%
26-09-25 €231.40 -0.79%
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
261.59USD
Average target price
278.86USD
Spread / Average Target
+6.60%

Quarterly revenue - Rate of surprise